WilmerHale Represents Karyopharm Therapeutics in Pricing of $150M of Convertible Senior Notes

WilmerHale Represents Karyopharm Therapeutics in Pricing of $150M of Convertible Senior Notes

Firm News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
We guide clients through today’s ever-changing debt markets, representing them in a broad variety of debt deals that range from complex financial structures to traditional loan transactions.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On Thursday, October 11, 2018, Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a clinical-stage pharmaceutical company, announced the pricing of $150 million aggregate principal amount of its 3.00% convertible senior notes due in 2025. The Notes were sold in a private offering to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933. Karyopharm also granted to the initial purchasers of the Notes a 13-day option to purchase up to an additional $22.5 million aggregate principal amount of the Notes.

The WilmerHale team representing Karyopharm in the sale consisted of Jason Kropp, Erika Robinson, John Sigel, Craig Hilts, Tim Kulis and Meghan Walsh. 

Read Karyopharm’s press release regarding the sale.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel